# A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

> **NCT04527380** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 101 (actual)

## Conditions studied

- Juvenile Psoriatic Arthritis
- Enthesitis Related Arthritis

## Interventions

- **DRUG:** Ixekizumab
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT04527380
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-13
- **Primary completion:** 2024-02-19
- **Final completion:** 2028-04
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04527380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04527380, "A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04527380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*